Until the rising nationwide anger over the price of medicines, Novo Nordisk (NVO) retained a comparatively low profile amongst drug makers. However as one of many three giant purveyors of insulin, the Danish firm has extra lately occupied an uncomfortable spot within the limelight. Together with Sanofi (SNY) and Eli Lilly (LLY), the corporate has been accused of value gouging, collusion, and indifference to folks with diabetes, a few of whom at the moment are driving from the U.S. to Canada to purchase insulin. The occasions prompted Novo chief govt Lars Fruergaard Jorgensen to go on a “listening tour” in late June to kind out the issue. We met with him on the outset of his tour and that is an edited model of our dialog.
Pharmalot: What do you hope to be taught on this tour?
Authoritative biopharma protection and evaluation, interviews with business pioneers, coverage evaluation, and first appears at innovative laboratories and early stage analysis
Subscriber-only networking occasions and panel discussions throughout the nation
Month-to-month subscriber-only stay chats with our reporters and consultants within the discipline
Discounted tickets to business occasions and early-bird entry to business studies